Third-line therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
Daniel Yick Chin Heng(University of Calgary), Toni K. Choueiri(Harvard University), Connor Wells(Queen Mary University of London), Ravindran Kanesvaran(University of Ioannina), Igor Stukalin(University of Calgary), Sumanta K. Pal(City of Hope), Ajjai Alva(Michigan Medicine), Aristotelis Bamias(National and Kapodistrian University of Athens), James Brugarolas(The University of Texas Southwestern Medical Center), Brian I. Rini(Vanderbilt University Medical Center), Georg A. Bjarnason(Sunnybrook Health Science Centre), Jae‐Lyun Lee(Ulsan College), Jennifer J. Knox(National Cancer Center), Lori Wood(Dalhousie University), Martin Smoragiewicz(University of Cambridge), Takeshi Yuasa(Japanese Foundation For Cancer Research), Sandy Srinivas(Stanford University), Reuben Broom(Auckland City Hospital), Frede Donskov(Aarhus University Hospital), Benoit Beuselinck(Universitair Ziekenhuis Leuven)
Cited by 3
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k